Randomized Clinical Trial on Three Different Platinum Based Chemotherapy in Advanced NSCLC in Bangladeshi Population

This Randomized Clinical Trial (RCT) was carried out in the Department of Medical Oncology at National Institute of Cancer Research and Hospital (NICRH), Mohakhali, Dhaka. Patients were enrolled from January 2012 for one year. Total 90 patients with above 18 years of age, both sexes presented with histologically confirmed stage IIIA, IIIB and IV NSCLC were enrolled and randomized (1:1:1) in to three arms. Cumulatively 26 patients were lost to follow up. Chemotherapy was given in 21 days interval (4-6 cycles). Toxicities were measured on Day 1, 7, 21, 28, 42, 3 months and on 6 months. Median follow up period was 6 months. Survival data was estimated by Kaplan-Meier method.

Significant G-1/2 Hb% was found in Day7 in TP (16.67%) and EP (10.52%) arm and in 6 months EP (31.58%) and TP (29.17%). WBC G-1/2 toxicity was found in EP (31.58%) and TP (20.83%) arm at 6 months. Similarly, in case of neutropenia and thrombocytopenia, GP arm was found to be significantly less toxic than TP and EP arm at 6 months. Response rate and survival data are provided in table 1.

In locally advanced or metastatic NSCLC response rate of platinum based combination therapy was satisfactory with increased survival than other reference trials along with lower G1/2 toxicity in GP arm followed by TP and EP in Bangladeshi Ethnic population.